Submitting an Investigational New Drug (IND) application is one of the most critical milestones for biotech and pharmaceutical companies. It marks the transition from discovery into first-in-human studies, a pivotal step that can determine the future of your program.

However, an IND that isn’t strategically prepared risks being placed on clinical hold by the FDA. These delays are costly, not only in terms of time and funding but also in diminished investor confidence. The reality is that most clinical holds are predictable and preventable. With the right regulatory expertise, sponsors can reduce their risks, avoid unnecessary delays, and speed up approval.

Here are the five most common reasons INDs are put on hold, and how the right preparation helps mitigate the risk.

1. Insufficient Preclinical Safety Data

The risk: Missing or poorly designed toxicology studies, or safety margins that don’t align with your clinical plan, raise immediate red flags.

How to de-risk:
Develop your nonclinical program strategically, ensuring your GLP toxicology studies are complete, well-documented, and clinically relevant. Regulatory experts can anticipate FDA expectations and highlight gaps before submission. An IND Readiness Assessment ensures your safety package is robust enough to support first-in-human trials.

2. CMC (Chemistry, Manufacturing, and Controls) Deficiencies

The risk: The FDA places intense scrutiny on drug quality and consistency. Missing stability data, vague process descriptions, or GMP compliance issues can stall clearance.

How to de-risk:
Start CMC planning early. Provide thorough data on characterization, stability, and manufacturing controls. A regulatory strategist can help map out what the FDA expects versus what can be staged later, ensuring your CMC section is ready for submission.

3. Inadequate Clinical Protocol Design

The risk: Even with strong science, a poorly justified clinical protocol can result in a hold. Common pitfalls include dose selection not supported by preclinical data, inappropriate inclusion/exclusion criteria, or insufficient safety monitoring.

How to de-risk:
Build your clinical protocol on a strong evidence base. Align trial design with FDA precedent and seek feedback in a pre-IND meeting. The right expertise ensures your protocol anticipates reviewer concerns and avoids missteps that trigger delays.

4. Incomplete or Disorganized Documentation

The risk: INDs sometimes fail not because of weak science, but because of disorganized submissions. Missing or inconsistent information slows reviewers and raises questions.

How to de-risk:
Think of your IND as a clear, compelling story told to regulators. Following the CTD format, cross-referencing carefully, and eliminating inconsistencies are critical. An IND Readiness Assessment provides an independent review to confirm your package is complete, coherent, and submission ready.

5. Failure to Address FDA Feedback

The risk: Ignoring or minimizing FDA guidance, whether from prior interactions or written comments, signals a lack of responsiveness and can quickly lead to a hold.

How to de-risk:
Engage the FDA proactively. Document how you’ve addressed their input and be transparent about data in progress. It’s critical to craft the right strategy and communications to build agency confidence.

Accelerating IND Clearance Through Expertise

Every day of delay slows clinical progress, increases burn rate, jeopardizes investor trust, and keeps patients waiting. The best way to de-risk your IND submission is through strategic, proactive preparation led by regulatory expertise.

At Lumanity, our IND Readiness Assessment is designed to:

  • Deliver a comprehensive cross-functional review across nonclinical, CMC, and clinical domains.
  • Identify gaps and risks early, before the FDA does.
  • Provide a tailored roadmap aligning development timelines with regulatory milestones.
  • Offer therapeutic area–specific insight based on evolving FDA expectations.
  • Leverage deep regulatory experience to distinguish between requirements, options, and potential red flags.

De-risking your IND is more than just a compliance exercise – it’s a strategic move to enhance speed, quality, and regulatory trust. With the right expertise, you can reduce risks, boost efficiency, and deliver innovative therapies to patients more efficiently.